Wesley A. Gray

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study

Seema Nayak, J M Griffiss, Jeffrey L. Blumer et al. · Antimicrobial Agents and Chemotherapy · 2017 · 48 citations · Full text

Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers

Amanda M. Healan, J. McLeod Griffiss, Howard M. Proskin et al. · Antimicrobial Agents and Chemotherapy · 2017 · 32 citations · Full text

A Phase 1 Pharmacokinetic and Safety Study of Extended-Duration, High-dose Cefixime for Cephalosporin-resistant Neisseria gonorrhoeae in the Pharynx

Lindley A. Barbee, Seema Nayak, Jeffrey L. Blumer et al. · Sexually Transmitted Diseases · 2018 · 21 citations · Full text

Klebsiella Pneumoniae, Antimicrobial Chemotherapy, Penicillin Data +17

Development and validation of an LC-MS/MS method for the simultaneous determination of bedaquiline and rifabutin in human plasma

Wesley A. Gray, Byron Waldorf, Manasa G. Rao et al. · Journal of Pharmaceutical and Biomedical Analysis · 2019 · 18 citations

Drug Discovery, Pharmacology, Human Plasma +10

A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation

George A. Yendewa, J. McLeod Griffiss, Michael R. Jacobs et al. · Journal of Global Antimicrobial Resistance · 2019 · 18 citations · Full text